Analysts at SunTrust Banks Inc. upgraded shares of Sarepta Therapeutics Inc. (NASDAQ: SRPT) from to Reduce today. With a rating of Reduce on the shares, Sarepta Therapeutics Inc. has a 52-week high of $56.80. The one-year price target of $44.46 …
Analysts at Cowen and Company upgraded shares of Sarepta Therapeutics Inc. (NASDAQ: SRPT) from Market Perform to Outperform today. The company currently has a rating of Outperform on the shares. The one-year price target of $44.46 is a decrease compared …
Wedbush analysts reiterated its Outperform rating on Sarepta Therapeutics Inc. (NASDAQ: SRPT) in a note to investors, making it one of the more closely watched stocks on Wall Street. The company currently has a rating of Outperform on the shares. …
WBB Securities analysts reiterated its Strong-Buy rating on Sarepta Therapeutics Inc. (NASDAQ: SRPT) in a note to investors, making it one of the more closely watched stocks on Wall Street. The company currently has a rating of Strong-Buy on the …
Sarepta Therapeutics (NASDAQ: SRPT) shares bounced off a new 52-week high of $56.80 today. A number of other analysts have commented on the stock recently, and the company has earned a consensus one-year price target of $44.46, lower than the …